KR20150117305A - Hcv 프로테아제 억제제 및 이의 용도 - Google Patents
Hcv 프로테아제 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20150117305A KR20150117305A KR1020157027032A KR20157027032A KR20150117305A KR 20150117305 A KR20150117305 A KR 20150117305A KR 1020157027032 A KR1020157027032 A KR 1020157027032A KR 20157027032 A KR20157027032 A KR 20157027032A KR 20150117305 A KR20150117305 A KR 20150117305A
- Authority
- KR
- South Korea
- Prior art keywords
- nitrogen
- membered
- independently selected
- oxygen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*1ccccn1 Chemical compound C*1ccccn1 0.000 description 9
- VKUOAWRNJRCALO-XNJMSXNASA-N C[C@H]([C@@H](C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3nc(-c3ccccc3)c2)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O)OC(/C=C/C)=O Chemical compound C[C@H]([C@@H](C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3nc(-c3ccccc3)c2)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O)OC(/C=C/C)=O VKUOAWRNJRCALO-XNJMSXNASA-N 0.000 description 2
- ALXTZRDIUBHJEE-FDPPHXCKSA-N CC#CC(NCC(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)=O Chemical compound CC#CC(NCC(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)=O ALXTZRDIUBHJEE-FDPPHXCKSA-N 0.000 description 1
- STVDZRZHZBRFPL-MBOHLOIDSA-N CC(C)(C)OC(N[C@@H](CC(C=C(C)C)=O)C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3ccn2)[C@@H]1C(N[C@H](C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CC(C=C(C)C)=O)C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3ccn2)[C@@H]1C(N[C@H](C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)=O STVDZRZHZBRFPL-MBOHLOIDSA-N 0.000 description 1
- YKUQFTDDTDKPOV-SRBXWPPTSA-O CC(C)(C)OC(N[C@@H](CN(C)C(C=C)=O)C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=[OH+])=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CN(C)C(C=C)=O)C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=[OH+])=O)=O YKUQFTDDTDKPOV-SRBXWPPTSA-O 0.000 description 1
- LLWCBRCUTKARBE-CHBUDNGTSA-N CC(C)(C)OC(N[C@H](CN(C)C(C#CC)=O)C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CN(C)C(C#CC)=O)C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)=O LLWCBRCUTKARBE-CHBUDNGTSA-N 0.000 description 1
- SWSXUUOUHLPOTL-KQVUSBAUSA-N CC(C)(C)OC(N[C@H](CN(C)C(C(C(F)(F)F)=C)=O)C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CN(C)C(C(C(F)(F)F)=C)=O)C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)=O SWSXUUOUHLPOTL-KQVUSBAUSA-N 0.000 description 1
- GUJIRWWUQHULAX-MJZAWOHOSA-N CC(C)[C@H](C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(C=C)=O Chemical compound CC(C)[C@H](C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(C=C)=O GUJIRWWUQHULAX-MJZAWOHOSA-N 0.000 description 1
- ZEZRTKSOVRMIFS-PANBGGKPSA-N CC([C@H](C1)[C@]1(C(NS(c1ccccc1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)N1C(CNC(C#CC)=O)=O)=O)=C Chemical compound CC([C@H](C1)[C@]1(C(NS(c1ccccc1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)N1C(CNC(C#CC)=O)=O)=O)=C ZEZRTKSOVRMIFS-PANBGGKPSA-N 0.000 description 1
- PUXNETOFKJFZLL-PLTHZAFVSA-N CCCC(NCC(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)=O Chemical compound CCCC(NCC(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)=O PUXNETOFKJFZLL-PLTHZAFVSA-N 0.000 description 1
- NQYHXCOJYVGJQD-NFTDCRROSA-N CC[C@](C=C)(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc2c(ccc(OC)c3)c3ccn2)N1C([C@H](CCC(C=C(C)C)=O)NC(OC(C)(C)C)=O)=O)=O Chemical compound CC[C@](C=C)(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc2c(ccc(OC)c3)c3ccn2)N1C([C@H](CCC(C=C(C)C)=O)NC(OC(C)(C)C)=O)=O)=O NQYHXCOJYVGJQD-NFTDCRROSA-N 0.000 description 1
- LDOJTVYUNZJEJH-YLEBNTKNSA-N COC([C@H](C[C@H](C1)Oc2c(cc(cc3)/C=C/CCCOC(N[C@H]4CNS(c(cccc5)c5[N+]([O-])=O)(=O)=O)=O)c3ccn2)N1C4=O)=O Chemical compound COC([C@H](C[C@H](C1)Oc2c(cc(cc3)/C=C/CCCOC(N[C@H]4CNS(c(cccc5)c5[N+]([O-])=O)(=O)=O)=O)c3ccn2)N1C4=O)=O LDOJTVYUNZJEJH-YLEBNTKNSA-N 0.000 description 1
- QMXSYYJQJKVTBZ-KATQCJQBSA-N COc(cc1)cc2c1c(O[C@H](C[C@H]1C(NC[C@](C3)([C@@H]3C=C)C(NS(c3ccccc3)(=O)=O)=O)=O)CN1C(CNC(C(c1ccccc1)Cl)=O)=O)cc(-c1ccccc1)n2 Chemical compound COc(cc1)cc2c1c(O[C@H](C[C@H]1C(NC[C@](C3)([C@@H]3C=C)C(NS(c3ccccc3)(=O)=O)=O)=O)CN1C(CNC(C(c1ccccc1)Cl)=O)=O)cc(-c1ccccc1)n2 QMXSYYJQJKVTBZ-KATQCJQBSA-N 0.000 description 1
- ZUAQSVSNLBSPMW-XDWWGYQNSA-N COc(cc1)cc2c1c(O[C@H](C[C@H]1C(N[C@](C3)([C@@H]3C=C)C(NS(C3CC3)(=O)=O)=O)=O)CN1C([C@H](CNC(C=C)=O)NC(OC1CCCC1)=O)=O)cc(-c1ccccc1)n2 Chemical compound COc(cc1)cc2c1c(O[C@H](C[C@H]1C(N[C@](C3)([C@@H]3C=C)C(NS(C3CC3)(=O)=O)=O)=O)CN1C([C@H](CNC(C=C)=O)NC(OC1CCCC1)=O)=O)cc(-c1ccccc1)n2 ZUAQSVSNLBSPMW-XDWWGYQNSA-N 0.000 description 1
- VIPRUBPMKKCGSN-KMRTVBBESA-N COc1cc2nc(-c3ccccc3)cc(O[C@H](CC3C(N[C@](C4)([C@@H]4C=C)C(NS(C4=CC4)(=O)=O)=O)=O)CN3C(C=C)=O)c2cc1 Chemical compound COc1cc2nc(-c3ccccc3)cc(O[C@H](CC3C(N[C@](C4)([C@@H]4C=C)C(NS(C4=CC4)(=O)=O)=O)=O)CN3C(C=C)=O)c2cc1 VIPRUBPMKKCGSN-KMRTVBBESA-N 0.000 description 1
- PIMSHOIYIPPQCQ-IQKHKQIISA-M C[C@H](C(N(C[C@@H](C1)Oc2c(ccc([O-])c3)c3nc(-c3ccccc3)c2)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)NC(C=C)=O Chemical compound C[C@H](C(N(C[C@@H](C1)Oc2c(ccc([O-])c3)c3nc(-c3ccccc3)c2)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)NC(C=C)=O PIMSHOIYIPPQCQ-IQKHKQIISA-M 0.000 description 1
- RNTDWGBAZGWRPZ-MBBGVVJMSA-N C[C@H](C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(C=C)=O Chemical compound C[C@H](C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(C=C)=O RNTDWGBAZGWRPZ-MBBGVVJMSA-N 0.000 description 1
- OWGRHYMRKBYWFX-QFPHAYAZSA-N C[C@H](C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)NC(C=C)=O Chemical compound C[C@H](C(N(C[C@@H](C1)Oc2cc(-c3ccccc3)nc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(c1ccccc1)(=O)=O)=O)=O)=O)NC(C=C)=O OWGRHYMRKBYWFX-QFPHAYAZSA-N 0.000 description 1
- VEZYHRFBYKTZHH-UHFFFAOYSA-N Cs1ccccc1 Chemical compound Cs1ccccc1 VEZYHRFBYKTZHH-UHFFFAOYSA-N 0.000 description 1
- DVYYFLUSDNZWMI-UHFFFAOYSA-N NC(c1c[s]c(F)n1)=O Chemical compound NC(c1c[s]c(F)n1)=O DVYYFLUSDNZWMI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1611007P | 2007-12-21 | 2007-12-21 | |
| US61/016,110 | 2007-12-21 | ||
| US1647307P | 2007-12-23 | 2007-12-23 | |
| US61/016,473 | 2007-12-23 | ||
| US6037108P | 2008-06-10 | 2008-06-10 | |
| US61/060,371 | 2008-06-10 | ||
| US9866808P | 2008-09-19 | 2008-09-19 | |
| US61/098,668 | 2008-09-19 | ||
| PCT/US2008/087725 WO2009082697A1 (en) | 2007-12-21 | 2008-12-19 | Hcv protease inhibitors and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107015717A Division KR101683559B1 (ko) | 2007-12-21 | 2008-12-19 | Hcv 프로테아제 억제제 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150117305A true KR20150117305A (ko) | 2015-10-19 |
Family
ID=40801568
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157027032A Ceased KR20150117305A (ko) | 2007-12-21 | 2008-12-19 | Hcv 프로테아제 억제제 및 이의 용도 |
| KR1020107015717A Expired - Fee Related KR101683559B1 (ko) | 2007-12-21 | 2008-12-19 | Hcv 프로테아제 억제제 및 이의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107015717A Expired - Fee Related KR101683559B1 (ko) | 2007-12-21 | 2008-12-19 | Hcv 프로테아제 억제제 및 이의 용도 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9163061B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2237667A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5755449B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20150117305A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104557861A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008340257B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0821559A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2709535A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1210141A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010006736A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ586231A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2515318C2 (cg-RX-API-DMAC7.html) |
| TW (2) | TW200932255A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009082697A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201004302B (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104557880A (zh) * | 2007-12-21 | 2015-04-29 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| WO2009082697A1 (en) | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| JP2012501654A (ja) * | 2008-09-05 | 2012-01-26 | アビラ セラピューティクス, インコーポレイテッド | 不可逆的インヒビターの設計のためのアルゴリズム |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8603737B2 (en) * | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| US9193740B2 (en) * | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
| MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| WO2011082285A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
| WO2012037259A1 (en) * | 2010-09-15 | 2012-03-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제 |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途 |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012166459A1 (en) * | 2011-05-27 | 2012-12-06 | Bristol-Myers Squibb Company | Tripeptides incorporating deuterium as inhibitors of hepatitis c virus |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| BR112015007887A2 (pt) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compostos úteis para produzir inibidores hcv protease |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| JP6768270B2 (ja) * | 2015-08-03 | 2020-10-14 | 学校法人神戸学院 | ビオチン直接結合型タンパク質活性調節物質 |
| US12441762B2 (en) * | 2019-06-07 | 2025-10-14 | University Of Massachusetts | Hepatitis c virus NS3/4A protease inhibitors |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7675491A (en) * | 1990-04-04 | 1991-10-30 | Chiron Corporation | Hepatitis c virus protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| US6211338B1 (en) | 1997-11-28 | 2001-04-03 | Schering Corporation | Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide |
| US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
| WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
| AU2001253621A1 (en) | 2000-04-19 | 2001-11-07 | Schering Corporation | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| MXPA03004299A (es) | 2000-11-20 | 2004-02-12 | Bristol Myers Squibb Co | Inhibidores de tripeptido de hepatitis c. |
| US6825347B2 (en) | 2001-05-21 | 2004-11-30 | Research Corporation Technologies, Inc. | Uronium and immonium salts for peptide coupling |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| MXPA04007163A (es) | 2002-01-23 | 2004-10-29 | Schering Corp | Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c. |
| US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| EP1497282A2 (en) | 2002-04-11 | 2005-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease |
| AU2003231123A1 (en) | 2002-04-25 | 2003-11-10 | Emory University | Semisynthetic protein-based site-directed probes for identification and inhibition of active sites, and methods therefor |
| US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| PL215228B1 (pl) | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003248535A1 (en) * | 2002-05-20 | 2003-12-12 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
| ES2315568T3 (es) | 2002-05-20 | 2009-04-01 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido. |
| WO2004013276A2 (en) | 2002-07-30 | 2004-02-12 | Morphosys Ip Gmbh | Novel tricistronic vectors and uses therefor |
| EP1408031A1 (en) * | 2002-10-09 | 2004-04-14 | 3 D Gene Pharma | Pyrolidine derivatives useful in treatment of hepatitis C virus infection |
| US7265152B2 (en) | 2002-11-01 | 2007-09-04 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
| US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
| JP4550824B2 (ja) | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎抑制化合物 |
| WO2004092728A2 (en) | 2003-04-07 | 2004-10-28 | Praecis Pharmaceuticals, Inc. | Methods of measuring the ability of a test compound to inactivate a biological target in cells of a subject |
| EP1615947A2 (en) | 2003-04-10 | 2006-01-18 | Boehringer Ingelheim International GmbH | Process for preparing macrocyclic compounds |
| ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| CL2004001161A1 (es) | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| US20050053617A1 (en) | 2003-05-28 | 2005-03-10 | Erik Depla | Modified HCV NS3 |
| US20050014136A1 (en) | 2003-05-28 | 2005-01-20 | Innogenetics N.V. | Modified HCV NS5 |
| US7273851B2 (en) | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| NZ546663A (en) | 2003-10-10 | 2010-01-29 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MXPA06005683A (es) | 2003-11-20 | 2006-12-14 | Schering Corp | Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c. |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1749007A2 (en) | 2004-03-30 | 2007-02-07 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| CN1984922A (zh) | 2004-05-20 | 2007-06-20 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸 |
| EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
| JP4914348B2 (ja) * | 2004-06-28 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類似体 |
| KR20070034119A (ko) | 2004-07-16 | 2007-03-27 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| JP4914355B2 (ja) | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類似体 |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| MX2007002371A (es) | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| US7189844B2 (en) | 2004-09-17 | 2007-03-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
| US7402568B2 (en) | 2004-09-29 | 2008-07-22 | Enanta Pharmaceuticals, Inc. | Bicyclic 9a-azalide derivatives |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN103172697A (zh) | 2005-03-08 | 2013-06-26 | 贝林格尔.英格海姆国际有限公司 | 制备大环化合物的方法 |
| US20090081636A1 (en) | 2005-04-11 | 2009-03-26 | Mingjun Huang | Pharmaceutical compositions for and methods of inhibiting HCV replication |
| AU2006242475B2 (en) * | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7592336B2 (en) * | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20060287248A1 (en) | 2005-06-02 | 2006-12-21 | Schering Corporation | Asymmetric dosing methods |
| JP2008545748A (ja) | 2005-06-02 | 2008-12-18 | シェーリング コーポレイション | C型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物 |
| US20070004635A1 (en) | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
| US20060281689A1 (en) | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US7772178B2 (en) | 2005-06-02 | 2010-08-10 | Schering Corporation | Pharmaceutical formulations and methods of treatment using the same |
| US20060276407A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| US20060276405A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
| WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20070021351A1 (en) | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| US8119602B2 (en) | 2005-06-02 | 2012-02-21 | Schering Corporation | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
| WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| US20080200497A1 (en) | 2005-07-20 | 2008-08-21 | Bailey Murray D | Hepatitis C Inhibitor Peptide Analogs |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| EP2305696A3 (en) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| EA200801050A1 (ru) | 2005-10-11 | 2008-12-30 | Интермьюн, Инк. | Соединения и способы ингибирования репликации вирусного гепатита с |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007089618A2 (en) | 2006-01-27 | 2007-08-09 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
| AR059430A1 (es) | 2006-02-09 | 2008-04-09 | Schering Corp | Novedosas combinaciones y metodos de inhibidores del vhc |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7687459B2 (en) | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US7662779B2 (en) | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
| CA2667165A1 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| JP5268927B2 (ja) | 2006-10-27 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
| WO2008057208A2 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100143886A1 (en) | 2007-03-09 | 2010-06-10 | Ludmerer Steven W | In vivo hcv resistance to anti-viral inhibitors |
| KR101396696B1 (ko) | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도 |
| MX2010006209A (es) | 2007-12-05 | 2010-08-10 | Enanta Pharm Inc | Derivados de quinoxalinilo. |
| WO2009082697A1 (en) | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| CN104557880A (zh) | 2007-12-21 | 2015-04-29 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8603737B2 (en) | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
-
2008
- 2008-12-19 WO PCT/US2008/087725 patent/WO2009082697A1/en not_active Ceased
- 2008-12-19 JP JP2010539883A patent/JP5755449B2/ja not_active Expired - Fee Related
- 2008-12-19 CA CA2709535A patent/CA2709535A1/en not_active Abandoned
- 2008-12-19 KR KR1020157027032A patent/KR20150117305A/ko not_active Ceased
- 2008-12-19 RU RU2010125106/04A patent/RU2515318C2/ru not_active IP Right Cessation
- 2008-12-19 TW TW97149689A patent/TW200932255A/zh unknown
- 2008-12-19 BR BRPI0821559-6A patent/BRPI0821559A2/pt active Search and Examination
- 2008-12-19 MX MX2010006736A patent/MX2010006736A/es active IP Right Grant
- 2008-12-19 EP EP08865122A patent/EP2237667A4/en not_active Withdrawn
- 2008-12-19 NZ NZ586231A patent/NZ586231A/xx not_active IP Right Cessation
- 2008-12-19 AU AU2008340257A patent/AU2008340257B2/en not_active Ceased
- 2008-12-19 KR KR1020107015717A patent/KR101683559B1/ko not_active Expired - Fee Related
- 2008-12-19 US US12/339,680 patent/US9163061B2/en not_active Expired - Fee Related
- 2008-12-19 TW TW103133572A patent/TW201518507A/zh unknown
- 2008-12-19 CN CN201410718124.3A patent/CN104557861A/zh active Pending
- 2008-12-19 CN CN200880127244.9A patent/CN101951770B/zh not_active Expired - Fee Related
-
2010
- 2010-06-17 ZA ZA2010/04302A patent/ZA201004302B/en unknown
-
2015
- 2015-02-02 JP JP2015018286A patent/JP2015113346A/ja not_active Ceased
- 2015-10-19 US US14/887,092 patent/US20160235805A1/en not_active Abandoned
- 2015-10-29 HK HK15110728.1A patent/HK1210141A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101951770A (zh) | 2011-01-19 |
| EP2237667A4 (en) | 2012-05-16 |
| KR20100131971A (ko) | 2010-12-16 |
| AU2008340257A1 (en) | 2009-07-02 |
| TW200932255A (en) | 2009-08-01 |
| KR101683559B1 (ko) | 2016-12-08 |
| BRPI0821559A2 (pt) | 2015-06-16 |
| RU2010125106A (ru) | 2012-01-27 |
| US20090306085A1 (en) | 2009-12-10 |
| JP2011509242A (ja) | 2011-03-24 |
| NZ586231A (en) | 2012-12-21 |
| WO2009082697A1 (en) | 2009-07-02 |
| JP2015113346A (ja) | 2015-06-22 |
| HK1210141A1 (en) | 2016-04-15 |
| ZA201004302B (en) | 2011-10-26 |
| CN104557861A (zh) | 2015-04-29 |
| CA2709535A1 (en) | 2009-07-02 |
| JP5755449B2 (ja) | 2015-07-29 |
| RU2515318C2 (ru) | 2014-05-10 |
| US9163061B2 (en) | 2015-10-20 |
| AU2008340257B2 (en) | 2015-06-11 |
| MX2010006736A (es) | 2010-10-15 |
| CN101951770B (zh) | 2014-12-31 |
| EP2237667A1 (en) | 2010-10-13 |
| US20160235805A1 (en) | 2016-08-18 |
| TW201518507A (zh) | 2015-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101683559B1 (ko) | Hcv 프로테아제 억제제 및 이의 용도 | |
| US8309685B2 (en) | HCV protease inhibitors and uses thereof | |
| JP5755450B2 (ja) | Hcvプロテアーゼ阻害剤およびその使用 | |
| US8293705B2 (en) | HCV protease inhibitors and uses thereof | |
| AU2015224437B2 (en) | HCV protease inhibitors and uses thereof | |
| AU2017203728A1 (en) | HCV protease inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20150930 Application number text: 1020107015717 Filing date: 20100715 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20151030 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20151208 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20170126 Patent event code: PE09021S02D |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20170525 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170728 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20170126 Comment text: Final Notice of Reason for Refusal Patent event code: PE06011S02I Patent event date: 20151208 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |